# A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

> **NCT05015621** · PHASE3 · UNKNOWN · sponsor: **Hutchison Medipharma Limited** · enrollment: 194 (estimated)

## Conditions studied

- Advanced Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Surufatinib plus Toripalimab
- **DRUG:** 5-fluorouracil, Calcium folinate and Irinotecan

## Key facts

- **NCT ID:** NCT05015621
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-18
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015621, "A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05015621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*